Beyond Chimeric Antigen Receptor T-Cell Therapy: Comprehensive Approaches for Community Oncology Practices in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Stream Link: https://event.arraylive.com/ap...

This satellite symposium will be broadcast live from the 2025 Community Oncology Conference in Lake Buena Vista, Florida. If you would like to attend in-person, please click here to register.

Program Description

Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma that mainly affects older adults. While first-line treatment with R-CHOP achieves a 50%–60% cure rate, there are still risks of patient mortality, disease that is refractory to initial therapy, and disease relapse within 2 years. Chimeric antigen receptor (CAR) T-cell therapy is effective in treating relapsed/refractory (R/R) DLBCL, however, its potential for relapse and barriers to widespread use highlight the need for alternative therapies. The treatment landscape for R/R DLBCL has since evolved with the introduction of targeted monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates. The optimal treatment sequence for R/R DLBCL therapies remains unclear as these novel agents have overlapping mechanisms of action, therapeutic targets, and approved indications that oncology pharmacists must distinguish within R/R DLBCL based on treatment sequencing recommendations and patient-specific considerations. Expert faculty will provide clinical insights for these therapies that may affect treatment selection for patients with R/R DLBCL, considering second- and third-line treatment options as well as adverse effects, dosing schedule, and supportive care requirements. This session will also provide oncology pharmacists in community-based settings with key dispensing and administration considerations for these agents to improve management of anticancer therapies in R/R DLBCL.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: April 29, 2025
Expiration date: June 29, 2025

Time to complete activity: 0.75 hour

Learner level: Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Identify immune-based therapies for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), focusing on their pharmacology, therapeutic positioning, and key dispensing/administration considerations
• Explore sequencing principles and patient-specific considerations to guide personalized treatment selection for individuals with R/R DLBCL who are not eligible for or have progressed after chimeric antigen receptor T-cell therapy
• Apply strategies to reduce treatment-related adverse events of immune-based therapies in R/R DLBCL including the use of premedication protocols, dosing adjustments, and patient counseling

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hour (0.075 CEU) under the ACPE universal activity number 0290-0000-25-016-L01-P. The activity is available for CE credit through June 29, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Brooke Adams, PharmD, BCOP, has the following financial relationships with commercial interests to disclose:
Consultant: Johnson and Johnson, Genmab (Advisory Boards)

Speakers Bureau: Pfizer

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Marlo Blazer, PharmD, BCOP

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Amy L. Morris, PharmD; Daphne Davis, PharmD; Crissy Wilson; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.


Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms